Clinical Trials

We specialize in clinical studies for patients diagnosed with asthma, heart disease and COPD.

Since its inception, Inspiration Research has successfully completed over 70 human clinical studies with leading global pharmaceutical and biotechnology companies including GlaxoSmithKline, Merck, Novartis, Boehringer Ingelheim, Amgen, AstraZeneca, Nycomed, Schering-Plough, and Forest Laboratories.

Despite the number of medications available, a substantial number of patients continue to have uncontrolled or poorly controlled asthma and or COPD. At Inspiration Research Ltd, we work with all the leading pharmaceutical/biotechnology companies to examine the latest asthma therapies with patients. A vital part of that process is to conduct studies to demonstrate the efficacy and safety of the new therapies.

Studies vary in length, ranging from 6 months to 3 years. In each study, there are a set number of on-site study visits. We are located in downtown Toronto, near the intersection of Spadina Ave. and College St. The duration of each visit depends on the number of procedures as stated by the study protocol. At the first study visit, the visit schedule and the duration of each visit will be provided to study participants. Reimbursement is provided for out-of-pocket expenses, usually between $50 – $100, at the end of each visit.

If you are interested in getting involved in a clinical trial please reach out! We are happy to explain any current opportunities and the eligibility criteria.

Contact Us

Bronchiectasis

Inspiration Research is enrolling people with Emphysema/ Chronic Bronchitis into a research study to evaluate an investigational drug.

You may be eligible if you are:

  •  40 years of age or older
  •   Currently using a daily maintenance of respiratory inhalers
  •   Able to attend on site visits
  •  Current or ex smoker

*Additional criteria may apply

Contact us to learn more!

Read More

COPD

Chronic obstructive pulmonary disease (COPD) is a central focus at Inspiration Research LTD and we have participated in more than 50 studies and routinely have opportunities for patients to participate.

Inspiration Research is enrolling people with COPD into a research study to evaluate an investigational drug.

You may be eligible if you are:

  •  40 years of age or older
  •   Currently using a daily maintenance of respiratory inhalers
  •   Able to attend on site visits
  •  Current or ex smoker

*Additional criteria may apply

Contact us to learn more!

We recently participated in a multi-centre trial that looked at the safety and efficacy of aclidinium bromide in patients with COPD and increased cardiovascular risk. To learn more about the study click here

Asthma

Inspiration Research is enrolling people with asthma into a research study to evaluate an investigational drug.

You may be eligible if you are:

  •   18 years of age and Up
  •   Currently using a daily maintenance inhaled steroid
  •   Able to attend on site visits
  •   A non-smoker for 1 year with limited smoking history

*Additional criteria may apply

Contact us to learn more!

DAP-CORONA

This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity, among those with confirmed SARS-CoV-2 infection.

3000 infected patients diagnosed with COVID-19, non-hospitalized at the time of enrollment, meeting all inclusion and no exclusion criteria will be randomized (1:1 allocation ratio) to receive either Dapsone or placebo tablets for 21 days, and will be followed up for 7 days after treatment termination for outcome assessment and up to 30 days for safety monitoring.

To be considered for this study you need to be

  • 40 +
  • Symptomatic with confirmed COVID-19 (SARS-COV-2 PCR positive) for at least 24 hrs. and no more than 7 days
  • If under 70 the presence of at least one co-morbidity

To learn more contact Sharmistha Biswas 1-866-327-2728 sharmistha.biswas@mail.mcgill.ca or view the website https://dapcorona.com/en/

This study has testing sites in Toronto, Montreal, High Point, North Carolina, Philadelphia, Pennsylvania, Phoenix, Arizona, Pittsburgh, Pennsylvania

Spokane, and Washington State.

Icon

Striving To Bring Care to Those Who Need it Most

Make An Appointment

Contact us to get involved with ongoing studies.

Contact Us